Enapotamab vedotin (HuMax-AXL-ADC)

Enapotamab vedotin (HuMax®-AXL-ADC) is an antibody-drug conjugate (ADC) targeted to AXL.  AXL is a unique receptor tyrosine kinase (RTK) that is aberrantly expressed in many solid tumor types and is implicated in tumor cell proliferation, migration, and invasion.1  Enapotamab vedotin is fully owned by Genmab, and the ADC technology is licensed from Seattle Genetics, Inc. 

Clinical studies
A Phase I/II study is currently ongoing in a variety of solid tumors.2  

1 Song X, Wang H, Logsdon CD, et al. Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Cancer. 2011;117(4):734-743.
2 US National Institutes of Health. HuMax®-AXL-ADC safety study in patients with solid tumors. https://clinicaltrials.gov/ct2/show/NCT02988817?term=genmab+axl&rank=1. Updated August 16, 2017. Accessed March 14, 2018.